The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial



Marson, Anthony ORCID: 0000-0002-6861-8806, Burnside, Girvan ORCID: 0000-0001-7398-1346, Appleton, Richard, Smith, Dave, Leach, John Paul, Sills, Graeme, Tudur-Smith, Catrin, Plumpton, Catrin, Hughes, Dyfrig A ORCID: 0000-0001-8247-7459, Williamson, Paula ORCID: 0000-0001-9802-6636
et al (show 10 more authors) (2021) The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. LANCET, 397 (10282). 1375 - 1386.

Access the full-text of this item by clicking on the Open Access link.
Item Type: Article
Divisions: Faculty of Health and Life Sciences
Faculty of Health and Life Sciences > Institute of Population Health
Faculty of Health and Life Sciences > Institute of Systems, Molecular and Integrative Biology
Depositing User: Symplectic Admin
Date Deposited: 17 May 2021 09:00
Last Modified: 21 Nov 2021 08:11
Open Access URL: https://www.thelancet.com/journals/lancet/article/...
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3123016